Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation

Megan Mulholland, Marie A C Depuydt, Gabriel Jakobsson, Irena Ljungcrantz, Andrietta Grentzmann, Fong To, Eva Bengtsson, Elin Jaensson Gyllenbäck, Caitríona Grönberg, Sara Rattik, David Liberg, Alexandru Schiopu, Harry Björkbacka, Johan Kuiper, Ilze Bot, Bram Slütter, Daniel Engelbertsen

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review


AIMS: The interleukin-1 receptor accessory protein (IL1RAP) is a co-receptor required for signalling through the IL-1, IL-33, and IL-36 receptors. Using a novel anti-IL1RAP-blocking antibody, we investigated the role of IL1RAP in atherosclerosis.

METHODS AND RESULTS: Single-cell RNA sequencing data from human atherosclerotic plaques revealed the expression of IL1RAP and several IL1RAP-related cytokines and receptors, including IL1B and IL33. Histological analysis showed the presence of IL1RAP in both the plaque and adventitia, and flow cytometry of murine atherosclerotic aortas revealed IL1RAP expression on plaque leucocytes, including neutrophils and macrophages. High-cholesterol diet fed apolipoprotein E-deficient (Apoe-/-) mice were treated with a novel non-depleting IL1RAP-blocking antibody or isotype control for the last 6 weeks of diet. IL1RAP blockade in mice resulted in a 20% reduction in subvalvular plaque size and limited the accumulation of neutrophils and monocytes/macrophages in plaques and of T cells in adventitia, compared with control mice. Indicative of reduced plaque inflammation, the expression of several genes related to leucocyte recruitment, including Cxcl1 and Cxcl2, was reduced in brachiocephalic arteries of anti-IL1RAP-treated mice, and the expression of these chemokines in human plaques was mainly restricted to CD68+ myeloid cells. Furthermore, in vitro studies demonstrated that IL-1, IL-33, and IL-36 induced CXCL1 release from both macrophages and fibroblasts, which could be mitigated by IL1RAP blockade.

CONCLUSION: Limiting IL1RAP-dependent cytokine signalling pathways in atherosclerotic mice reduces plaque burden and plaque inflammation, potentially by limiting plaque chemokine production.

TidskriftCardiovascular Research
StatusE-pub ahead of print - 2024 apr. 2

Bibliografisk information

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

Ämnesklassifikation (UKÄ)

  • Kardiologi


Utforska forskningsämnen för ”Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här